Key facts
- This page summarizes venBio Global Strategic Fund III, L.P.'s Form 4 filing for Elevation Oncology, Inc. (ELEV).
- 1 reported transaction and 0 derivative rows are listed below.
- Accepted by SEC: 27 May 2022, 19:20.
venBio Global Strategic Fund III, L.P. - 25 May 2022 Form 4 Insider Report for Elevation Oncology, Inc. (ELEV)
- Reporting relationship
- 10%+ Owner
- Issuer ticker
- ELEV
- Reported as of
- 25 May 2022
- Net transaction value
- -$2,897,806
- SEC form
- 4
- Accepted by SEC
- 27 May 2022, 19:20:33 UTC
- Prior SEC filing
- 25 Oct 2021
- Next SEC filing
- 10 Jun 2022
- Source filing
- View source filing
- Reporting owner signature
- venBio Global Strategic Fund III, L.P., by: venBio Global Strategic GP III, L.P., its general partner, by: venBio Global Strategic GP III, Ltd., its general partner, by: /s/ David Pezeshki, as attorney-in-fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
venBio Global Strategic Fund III, L.P. filed Form 4 for Elevation Oncology, Inc. (ELEV) on 27 May 2022.
Change
- Previous filing in this sequence was filed on 25 Oct 2021.
- Current net transaction value: -$2,897,806.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
ELEV
transaction
Common Stock
Sale
- Transaction value
- $2,897,806
- Shares
- -702,737
- Change %
- -27%
- Price
- $4.12
- Shares after
- 1,905,430
- Date
- 25 May 2022
- Ownership
- Direct
- Footnotes
- F1, F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Section 16 status
venBio Global Strategic Fund III, L.P. is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may still apply in specific circumstances.
Explanation of responses 2 footnotes
Footnote F1
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.00 to $4.37, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein.
Footnote F2
The shares are held by venBio Global Strategic Fund III, L.P. venBio Global Strategic GP III, L.P. is the sole general partner of venBio Global Strategic Fund III, L.P. and venBio Global Strategic GP III, Ltd. is the sole general partner of venBio Global Strategic GP III, L.P. Each of Corey Goodman, Robert Adelman and Aaron Royston is a director of venBio Global Strategic GP III, Ltd. Each of venBio Global Strategic GP III, L.P., venBio Global Strategic GP III, Ltd, Dr. Goodman, Dr. Adelman and Dr. Royston disclaims beneficial ownership of such securities, except to the extent of its/his indirect pecuniary interest therein.